Beximco Completes Sanofi Bangladesh Acquisition
Beximco Completes Sanofi Bangladesh Acquisition
Beximco Completes Sanofi Bangladesh Acquisition

News

Beximco Completes Sanofi Bangladesh Acquisition

17 Nov, 2021

Published over 5 years ago. See the latest and most current information on News.

Beximco Pharmaceuticals Ltd has announced that the company has now completed its acquisition of the majority stake in Sanofi Bangladesh, in line with the company’s strategy to expand core capabilities and product offerings.

Mr Nazmul Hassan MP, Beximco Pharma MD, commented: "The completion of this deal - the second acquisition in Beximco Pharma’s history - is a significant moment. We have a clear strategy to continue our diversification and expansion while strengthening our position as a market-leading pharma company in Bangladesh. The acquisition of a majority stake in Sanofi Bangladesh is precisely in line with this strategy, strengthening our position in key therapeutic areas to drive sustainable revenue and profit growth. We look forward to welcoming over 800 skilled and diligent Sanofi Bangladesh employees to our existing workforce. As an enlarged group, we are excited to continue our growth trajectory by delivering affordable treatments and breakthrough therapies in our growing domestic market."

More information online

Latest News

LMUK 51.7 Nov 2026

Explore our Digital Edition

Discover the latest news and research

Digital edition

Explore Our Other Sites

Envirotech Online
Phenol on the ground: what a COMAH prosecution shows about soil data as evidence
Explore more Arrow
Pollution Solutions Online
Pump and mixer service at paper mill set to reach 40 years
Explore more Arrow
Petro Online
Hydrogen sulphide deaths expose the gaps in gas detection during non-routine work
Explore more Arrow
Chromatography Today
High-load peptide purification
Explore more Arrow